Clinical Research Directory
Browse clinical research sites, groups, and studies.
Diagnosis of Metastatic Tumors on 68Ga-FAPI-RGD PET-CT and Radioligand Therapy With 177Lu-FAPI-RGD
Sponsor: Peking Union Medical College Hospital
Summary
FAP and RGD are overexpressed in many tumor tissues. This study is intended to conduct preliminary clinical transformation and internal irradiation dosimetry research on 177Lu-FAPI-RGD--a new dual-targeted 177Lu therapeutic drug for the first time in the world.
Official title: Diagnosis of Metastatic Tumors on 68Ga-FAPI-RGD PET-CT and Radioligand Therapy
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2024-05-01
Completion Date
2025-02-01
Last Updated
2024-10-15
Healthy Volunteers
No
Interventions
68Ga-FAPI-RGD for PET / CT scan and 177Lu-FAPI-RGD for therapy
Patients with positive results were screened with 68Ga-FAPI PET / CT, and 2.22-3.33GBq(60mci-100mCi) 177Lu-FAPI-RGD was injected intravenously for therapy after contraindications were excluded and informed consent was signed.
Locations (1)
Chinese Academy of Medical Science & Peking Union Medical College Hospital
Beijing, Beijing Municipality, China